PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20952680-4	2010	Second, specific pharmacological inhibition of SHP-1 enzymatic activity via the cancer drug sodium stibogluconate potently augmented Treg suppressor activity both in vivo and ex vivo.	Antimony Sodium Gluconate	92-113	protein tyrosine phosphatase, non-receptor type 6	Mus musculus	47-52	
20421638-1	2010	Src homology region 2 domain-containing phosphatase 1 (SHP-1) has been implicated as a potential cancer therapeutic target by its negative regulation of immune cell activation and the activity of the SHP-1 inhibitor sodium stibogluconate that induced IFN-gamma(+) cells for anti-tumor action.	Antimony Sodium Gluconate	216-237	protein tyrosine phosphatase, non-receptor type 6	Mus musculus	55-60	
20421638-1	2010	Src homology region 2 domain-containing phosphatase 1 (SHP-1) has been implicated as a potential cancer therapeutic target by its negative regulation of immune cell activation and the activity of the SHP-1 inhibitor sodium stibogluconate that induced IFN-gamma(+) cells for anti-tumor action.	Antimony Sodium Gluconate	216-237	protein tyrosine phosphatase, non-receptor type 6	Mus musculus	200-205	
19514839-1	2009	Sodium stibogluconate (SSG), an inhibitor of SHP-1 that negatively regulates cytokine signaling and immunity, suppressed growth of murine Renca tumors in combination with interleukin-2 (IL-2) via a T-cell-dependent mechanism.	Antimony Sodium Gluconate	0-21	protein tyrosine phosphatase, non-receptor type 6	Mus musculus	45-50	
19514839-1	2009	Sodium stibogluconate (SSG), an inhibitor of SHP-1 that negatively regulates cytokine signaling and immunity, suppressed growth of murine Renca tumors in combination with interleukin-2 (IL-2) via a T-cell-dependent mechanism.	Antimony Sodium Gluconate	23-26	protein tyrosine phosphatase, non-receptor type 6	Mus musculus	45-50	
11544330-1	2001	Using in vitro protein tyrosine phosphatase (PTPase) assays, we found that sodium stibogluconate, a drug used in treatment of leishmaniasis, is a potent inhibitor of PTPases Src homology PTPase1 (SHP-1), SHP-2, and PTP1B but not the dual-specificity phosphatase mitogen-activated protein kinase phosphatase 1.	Antimony Sodium Gluconate	75-96	protein tyrosine phosphatase, non-receptor type 6	Mus musculus	196-201	
11544330-2	2001	Sodium stibogluconate inhibited 99% of SHP-1 activity at 10 micrograms/ml, a therapeutic concentration of the drug for leishmaniasis.	Antimony Sodium Gluconate	0-21	protein tyrosine phosphatase, non-receptor type 6	Mus musculus	39-44	
23766558-5	2013	RESULTS: Inhibition of SHP-1 by the specific pharmacological inhibitor sodium stibogluconate did not significantly enhance platelet-endothelium interaction in vivo under physiological conditions but led to an augmented fraction of rolling platelets in TNFalpha -induced systemic inflammation.	Antimony Sodium Gluconate	71-92	protein tyrosine phosphatase, non-receptor type 6	Mus musculus	23-28